← Leaderboards
Alan R Fritzberg
Neorx Corporation
$1,514,682
Attributed
$1,514,682
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,514,682 · 2
By mechanism
R44$1,514,682 · 2
Top collaborators
No co-investigators on record.
Most similar at Neorx Corporation
Same institution · by research overlap
- Thomas P Quinn$3,207,797
- Donald B Axworthy$108,679
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseMonoclonal AntibodyBiotinBinding ProteinsNeoplasm /Cancer ImmunotherapyYttriumChimeric ProteinsClinical ResearchNonhodgkin'S LymphomaHuman SubjectProtein PurificationCd AntigensAntigen Antibody ReactionFlow CytometryImmunomodulatorsBiotechnologyBismuthChemical SynthesisDrug Screening /EvaluationAlpha RadiationLeadMetastasisNeoplasm /Cancer RadioimmunotherapyNeoplasm /Cancer Radionuclide Therapy
Grant awards (5)
PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA$358,187
R44 · FY2002 · CA
PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA$725,196
R44 · FY2001 · CA
ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212$314,561
R44 · FY2001 · CA
PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA$104,167
R44 · FY2000 · CA
ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212$12,571
R44 · FY2000 · CA